Resumo:
En
|
Texto:
En
|
PDF:
En
ABSTRACT Introduction: The aim of this study was to assess the impact of aortic angulation (AA) on periprocedural and in-hospital complications as well as mortality of patients undergoing Evolut™ R valve implantation. Methods: A retrospective study was conducted on 264 patients who underwent transfemoral-approach transcatheter aortic valve replacement with self-expandable valve at our hospital between August 2015 and August 2022. These patients underwent multislice computer tomography scans to evaluate AA. Transcatheter aortic valve replacement endpoints, device success, and clinical events were assessed according to the definitions provided by the Valve Academic Research Consortium-3. Cumulative events included paravalvular leak, permanent pacemaker implantation, new-onset stroke, and in-hospital mortality. Patients were divided into two groups, AA ≤ 48° and AA > 48°, based on the mean AA measurement (48.3±8.8) on multislice computer tomography. Results: Multivariable logistic regression analysis was performed to identify predictors of cumulative events, utilizing variables with a P-value < 0.2 obtained from univariable logistic regression analysis, including AA, age, hypertension, chronic renal failure, and heart failure. AA (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 0.89-3.38, P=0.104), age (OR: 1.04, 95% CI: 0.99-1.10, P=0.099), hypertension (OR: 1.66, 95% CI: 0.82-3.33, P=0.155), chronic renal failure (OR: 1.82, 95% CI: 0.92-3.61, P=0.084), and heart failure (OR: 0.57, 95% CI: 0.27-1.21, P=0.145) were not found to be significantly associated with cumulative events in the multivariable logistic regression analysis. Conclusion: This study demonstrated that increased AA does not have a significant impact on intraprocedural and periprocedural complications of patients with new generation self-expandable valves implanted. Introduction (AA inhospital Evolut implantation Methods 26 transfemoralapproach transfemoral approach selfexpandable self expandable 201 2022 endpoints success Consortium3. Consortium3 Consortium 3. 3 Consortium-3 leak newonset onset stroke groups 48 48.3±8.8 48388 8 (48.3±8.8 Results Pvalue P value 02 0 2 0. odds OR [OR] 173 1 73 1.73 95 CI [CI] 0.893.38, 089338 0.89 3.38, 89 38 0.89-3.38 P=0.104, P0104 P=0.104 , 104 P=0.104) (OR 04 1.04 0.991.10, 099110 0.99 1.10, 99 10 0.99-1.10 P=0.099, P0099 P=0.099 099 P=0.099) 166 66 1.66 0.823.33, 082333 0.82 3.33, 82 33 0.82-3.33 P=0.155, P0155 P=0.155 155 P=0.155) 182 1.82 0.923.61, 092361 0.92 3.61, 92 61 0.92-3.61 P=0.084, P0084 P=0.084 084 P=0.084) 057 57 0.57 0.271.21, 027121 0.27 1.21, 27 21 0.27-1.21 P=0.145 P0145 145 Conclusion implanted 20 202 Consortium- 4 48.3±8. 4838 (48.3±8. [OR 17 7 1.7 9 [CI 893 0.893.38 08933 089 0.8 338 3.38 0.89-3.3 P010 P=0.10 1.0 991 0.991.10 09911 0.9 110 1.10 0.99-1.1 P009 P=0.09 09 16 6 1.6 823 0.823.33 08233 082 333 3.33 0.82-3.3 P015 P=0.15 15 18 1.8 923 0.923.61 09236 092 361 3.61 0.92-3.6 P008 P=0.08 08 05 5 0.5 271 0.271.21 02712 027 121 1.21 0.27-1.2 P=0.14 P014 14 48.3±8 483 (48.3±8 1. 0.893.3 0893 3.3 0.89-3. P01 P=0.1 0.991.1 0991 11 1.1 0.99-1. P00 P=0.0 0.823.3 0823 0.82-3. 0.923.6 0923 36 3.6 0.92-3. 0.271.2 0271 12 1.2 0.27-1. 48.3± (48.3± 0.893. 0.89-3 P0 P=0. 0.991. 0.99-1 0.823. 0.82-3 0.923. 0.92-3 0.271. 0.27-1 48.3 (48.3 0.893 0.89- P=0 0.991 0.99- 0.823 0.82- 0.923 0.92- 0.271 0.27- 48. (48. P= (48 (4 (